Drugs Affecting Blood and Blood Formation Practice Questions

Q: Oral factor Xa inhibitor is:

Rivaroxaban. ***Rivaroxaban*** - **Rivaroxaban** is a direct oral anticoagulant (DOAC) that specifically inhibits **factor Xa**, preventing thrombin generation and clot formation. - It is administered **orally** and is widely used for preventing and treating venous thromboembolism and stroke in atrial fibrillation. *Bivalirudin* - **Bivalirudin** is a **direct thrombin inhibitor** (DTI), not a factor Xa inhibitor. - It is administered **intravenously**, primarily used in percutaneous coronary interventions. *Dabigatran* - **Dabigatran** is an **oral direct thrombin inhibitor** (DTI), which directly inhibits thrombin (factor IIa). - It does not inhibit factor Xa; its mechanism of action is distinct from that of factor Xa inhibitors. *Fondaparinux* - **Fondaparinux** is an **indirect factor Xa inhibitor** that requires antithrombin for its anticoagulant activity. - It is administered **subcutaneously**, distinguishing it from oral factor Xa inhibitors like rivaroxaban.

Q: Coagulation testing is needed for:

Lepirudin (direct thrombin inhibitor). ***Lepirudin (direct thrombin inhibitor)*** - **Lepirudin**, being a direct thrombin inhibitor, necessitates **coagulation testing** (such as aPTT) to monitor its anticoagulant effect and adjust dosing, especially in patients with renal impairment. - Its narrow therapeutic window and potential for bleeding complications require careful monitoring to ensure patient safety and drug efficacy, as it lacks a specific antidote. *Dabigatran (oral anticoagulant)* - **Dabigatran** is a **direct oral anticoagulant (DOAC)** that typically does not require routine coagulation monitoring due to its predictable pharmacokinetic and pharmacodynamic profiles. - While specific tests can assess its effect in emergencies, they are not part of standard management, distinguishing it from drugs requiring regular monitoring. *Enoxaparin (low molecular weight heparin)* - **Enoxaparin**, a **low molecular weight heparin (LMWH)**, usually does not require routine coagulation monitoring in most patients due to its predictable dose-response relationship. - Monitoring with anti-Xa levels may be considered in specific populations, such as those with renal insufficiency, extremes of weight, or in pediatric and pregnant patients. *Fondaparinux (synthetic pentasaccharide)* - **Fondaparinux** is a synthetic pentasaccharide that **does not require routine coagulation monitoring** as its anticoagulant effect is highly predictable and dose-dependent. - Its action is mediated through selective inhibition of **Factor Xa**, and standard coagulation tests like aPTT or PT are not sensitive to its effects.

Q: All are used in management of overdosage of Fibrinolytics except?

DDAVP. ***DDAVP*** - **DDAVP (Desmopressin)** is primarily used to treat certain bleeding disorders like **von Willebrand disease** and **hemophilia A** by increasing factor VIII and von Willebrand factor. - It does not directly counteract the fibrinolytic activity or mechanisms involved in **fibrinolytic overdose**. *Epsilon amino Caproic Acid* - **Epsilon aminocaproic acid (EACA)** is an **antifibrinolytic agent** that inhibits plasminogen activation, thus preventing the breakdown of fibrin clots. - It is often used to treat bleeding due to hyperfibrinolysis, including that caused by **fibrinolytic overdose**. *Tranexamic Acid* - **Tranexamic acid (TXA)** is another potent **antifibrinolytic agent** that works by reversibly blocking lysine binding sites on plasminogen, preventing its conversion to plasmin. - It is frequently used to manage and prevent excessive bleeding, including in situations of **fibrinolytic overdose**. *FFP* - **Fresh frozen plasma (FFP)** contains all coagulation factors, including **fibrinogen** and other factors consumed or degraded during fibrinolytic therapy. - It is used to replenish clotting factors and improve hemostasis, making it a critical component in managing severe bleeding from **fibrinolytic overdose**.

Q: Which of the following drugs is used for treatment of cancer associated thromboembolism?

LMW heparin. ***LMW heparin*** - **Low molecular weight heparin (LMWH)** is the **preferred anticoagulant for cancer-associated thrombosis** due to its superior efficacy. - It has a more predictable pharmacokinetic profile compared to unfractionated heparin and is administered subcutaneously. *Direct factor Xa inhibitors* - While effective for general venous thromboembolism (VTE) treatment, some direct oral anticoagulants (DOACs) like factor Xa inhibitors (e.g., rivaroxaban, apixaban) may be considered but have shown mixed results in comparative studies with LMWH for cancer patients, especially those with gastrointestinal cancers, presenting a **higher risk of major bleeding**. - **LMWH** remains the **first-line choice**, especially in patients with active cancer, given the evidence for its greater efficacy and safety profile in this specific population. *Warfarin* - **Warfarin** is generally **not recommended** as a first-line treatment for cancer-associated thromboembolism due to its **drug interactions**, need for frequent monitoring (INR), and slower onset of action. - Patients with cancer often have fluctuating nutritional status, hepatic dysfunction, and receive other medications that can significantly impact warfarin's effectiveness and safety. *Anti-thrombin III inhibitors* - **Antithrombin III inhibitors** (e.g., antithrombin concentrate) are primarily used in specific conditions like **hereditary antithrombin deficiency** or in cases of heparin resistance. - They are **not a standard treatment** for cancer-associated thromboembolism in the general population of cancer patients.

Q: A patient on long-term anticoagulation therapy has a serious gastrointestinal bleed. Which medication should be administered to reverse the effects of warfarin?

Vitamin K. ***Vitamin K*** - **Vitamin K** is the **specific antidote for warfarin** because warfarin exerts its anticoagulant effect by inhibiting **Vitamin K epoxide reductase**, an enzyme essential for reactivating Vitamin K. - Administering Vitamin K helps to overcome this inhibition, allowing for the synthesis of **functional clotting factors II, VII, IX, and X** and thus reversing the anticoagulation. - **Onset of action:** 6-24 hours for full effect, providing sustained reversal. - **Dose:** 10 mg IV for serious bleeding. *Protamine sulfate* - **Protamine sulfate** is used to reverse the anticoagulant effects of **heparin**, not warfarin. - It works by forming a stable ion pair with heparin, neutralizing its activity. *Fresh frozen plasma (FFP)* - While **FFP** can provide **clotting factors** for immediate hemostatic effect in life-threatening bleeding, it is **not a specific reversal agent** for warfarin. - FFP is used as an **adjunct** when rapid correction is needed before Vitamin K takes effect, but it does not address the underlying mechanism of warfarin toxicity. - **Vitamin K remains the definitive pharmacological reversal agent** for warfarin anticoagulation. *Aminocaproic acid (antifibrinolytic)* - **Aminocaproic acid** is an **antifibrinolytic agent** that inhibits the breakdown of clots by blocking plasminogen activation. - It is used to manage bleeding due to **fibrinolysis** (e.g., in conditions like DIC or during surgery), but it does **not reverse the anticoagulant effects** of warfarin.

Q: Which anticoagulant is recommended for preventing thromboembolism in patients with mechanical heart valves?

Warfarin. ***Warfarin*** - **Warfarin** is a vitamin K antagonist that effectively prevents thrombosis on the high-thrombogenic surface of mechanical heart valves. - Its efficacy in this specific patient population is well-established, with **dosing adjusted** to achieve a target international normalized ratio (INR) of 2.5-3.5. *Aspirin* - While aspirin has antiplatelet effects, it is generally **insufficient as monotherapy** for thrombosis prevention in patients with mechanical heart valves. - It is sometimes used as an **adjunctive therapy** with warfarin but does not replace it as the primary anticoagulant. *Rivaroxaban* - **Direct oral anticoagulants (DOACs)** like rivaroxaban are generally **contraindicated** in patients with mechanical heart valves due to increased risk of thromboembolism and bleeding complications. - Studies have shown **inferiority** of DOACs compared to warfarin in this population. *Dabigatran* - Similar to rivaroxaban, **dabigatran** is a direct thrombin inhibitor and is **not recommended** for patients with mechanical heart valves. - Clinical trials have demonstrated an **increased risk of stroke and bleeding** with dabigatran compared to warfarin in this setting.

Q: A patient with atrial fibrillation is prescribed warfarin. What is the PRIMARY factor that requires the most frequent monitoring to assess warfarin's anticoagulant effect?

INR (International Normalized Ratio). ***INR (International Normalized Ratio)*** - The **INR** is the most crucial test for monitoring **warfarin's anticoagulant effect**, reflecting the activity of the extrinsic coagulation pathway. - Regular monitoring ensures the patient's **INR** remains within the therapeutic range (typically 2.0-3.0 for atrial fibrillation) to prevent both thrombotic events and bleeding complications. *Liver function* - While relevant for assessing overall liver health and **warfarin metabolism**, liver function tests are not the primary, most frequent monitoring parameter for its **anticoagulant effect**. - **Warfarin** is metabolized in the liver, but routine, frequent monitoring of liver enzymes (e.g., ALT, AST) is not prioritized over **INR** for dose adjustments. *Potassium levels* - **Potassium levels** are not directly affected by **warfarin** and are not used to assess its anticoagulant efficacy or guide dosing. - Electrolyte imbalances, including potassium, are generally assessed for other medical conditions or drug side effects. *Blood pressure monitoring* - **Blood pressure** is important for overall cardiovascular health and to assess bleeding risk, particularly in patients on anticoagulants. - However, it does not directly measure the **anticoagulant effect** of **warfarin** on clotting factors.

Q: What is the primary mechanism of action of warfarin?

Inhibition of vitamin K-dependent clotting factors. ***Inhibition of vitamin K-dependent clotting factors*** - Warfarin works by inhibiting the enzyme **vitamin K epoxide reductase**, which is essential for the activation of vitamin K. - Activated vitamin K is a **cofactor** for the gamma-carboxylation of clotting factors II, VII, IX, and X, as well as proteins C and S, which are crucial for their function. *Activation of plasminogen* - This is the primary mechanism of **fibrinolytic drugs** (e.g., streptokinase, alteplase), which break down existing clots. - Warfarin's role is to **prevent clot formation**, not to dissolve them. *Inhibition of platelet aggregation* - This is the main mechanism of **antiplatelet drugs** such as aspirin or clopidogrel. - Warfarin affects the **coagulation cascade** and the production of clotting factors, not directly platelet function. *Inhibition of thrombin* - This is the action of **direct thrombin inhibitors** (e.g., dabigatran, argatroban). - While thrombin is a key clotting factor, warfarin's action is upstream in the coagulation cascade by reducing the synthesis of thrombin rather than directly inhibiting its activity.

Q: A 32-year-old woman is diagnosed with iron deficiency anemia and is prescribed oral iron supplementation. Which form of iron is most commonly prescribed for oral administration?

Ferrous sulfate. ***Ferrous sulfate*** - **Ferrous sulfate** is the **most commonly prescribed** oral iron supplement worldwide due to its excellent bioavailability, proven efficacy, and low cost. - It contains approximately **20% elemental iron** and is readily absorbed in the duodenum and proximal jejunum. - Its long-standing use, extensive clinical experience, and cost-effectiveness make it the **first-line choice** for treating iron deficiency anemia. *Ferric citrate* - **Ferric citrate** is a ferric (Fe³⁺) form with **lower bioavailability** compared to ferrous (Fe²⁺) salts. - It is primarily used as a **phosphate binder** in patients with chronic kidney disease rather than as a first-line treatment for iron deficiency anemia. *Iron dextran* - **Iron dextran** is an **intravenous iron preparation** and is not suitable for oral administration. - It is reserved for patients with severe iron deficiency, intolerance to oral iron, malabsorption syndromes, or when rapid iron repletion is needed. *Ferrous fumarate* - **Ferrous fumarate** is also an effective oral iron supplement containing approximately **33% elemental iron** (higher than ferrous sulfate). - It has comparable bioavailability and efficacy to ferrous sulfate. - While equally effective, **ferrous sulfate** remains more commonly prescribed due to lower cost and greater availability in most healthcare settings.

Q: What are the effects of niacin on HDL and triglycerides in the management of familial combined hyperlipidemia?

Increases HDL; lowers triglycerides. Correct: Increases HDL; lowers triglycerides - Niacin (nicotinic acid) is known for its efficacy in significantly **raising high-density lipoprotein (HDL)** levels, typically by 15-35% [1]. - It also has a potent effect on **reducing triglyceride** levels by 20-50%, making it beneficial in dyslipidemias where both are deranged [1]. - This dual action makes niacin particularly useful in familial combined hyperlipidemia [2]. Incorrect: Decreases HDL; raises triglycerides - This option describes effects that are the opposite of niacin's known pharmacological actions on lipid profiles. - Niacin is clinically used to improve, not worsen, these lipid parameters. Incorrect: No significant effect on HDL; minor effect on triglycerides - This statement underestimates niacin's impact, as its primary clinical utility is derived from its substantial effects on both HDL increase and triglyceride reduction [1]. - Although it has varied effects, its impact is far from minor or insignificant on these lipid components. Incorrect: Increases both HDL and triglycerides - While niacin raises HDL, it consistently **lowers triglycerides**, particularly in conditions like familial combined hyperlipidemia where triglyceride elevation is a key feature [2]. - Therefore, the claim that it increases both is incorrect due to its opposite effect on triglycerides.

Question 1

Oral factor Xa inhibitor is:

Accepted Answer

Rivaroxaban

Answer

Bivalirudin

Answer

Dabigatran

Answer

Fondaparinux

Question 2

Coagulation testing is needed for:

Accepted Answer

Lepirudin (direct thrombin inhibitor)

Answer

Dabigatran (oral anticoagulant)

Answer

Enoxaparin (low molecular weight heparin)

Answer

Fondaparinux (synthetic pentasaccharide)

Question 3

All are used in management of overdosage of Fibrinolytics except?

Accepted Answer

DDAVP

Answer

Epsilon amino Caproic Acid

Answer

Tranexamic Acid

Answer

FFP

Question 4

Which of the following drugs is used for treatment of cancer associated thromboembolism?

Accepted Answer

LMW heparin

Answer

Direct factor Xa inhibitors

Answer

Warfarin

Answer

Anti-thrombin III inhibitors

Question 5

A patient on long-term anticoagulation therapy has a serious gastrointestinal bleed. Which medication should be administered to reverse the effects of warfarin?

Accepted Answer

Vitamin K

Answer

Protamine sulfate

Answer

Fresh frozen plasma (FFP)

Answer

Aminocaproic acid (antifibrinolytic)

Question 6

Which anticoagulant is recommended for preventing thromboembolism in patients with mechanical heart valves?

Accepted Answer

Warfarin

Answer

Aspirin

Answer

Rivaroxaban

Answer

Dabigatran

Question 7

A patient with atrial fibrillation is prescribed warfarin. What is the PRIMARY factor that requires the most frequent monitoring to assess warfarin's anticoagulant effect?

Accepted Answer

INR (International Normalized Ratio)

Answer

Liver function

Answer

Potassium levels

Answer

Blood pressure monitoring

Question 8

What is the primary mechanism of action of warfarin?

Accepted Answer

Inhibition of vitamin K-dependent clotting factors

Answer

Activation of plasminogen

Answer

Inhibition of platelet aggregation

Answer

Inhibition of thrombin

Question 9

A 32-year-old woman is diagnosed with iron deficiency anemia and is prescribed oral iron supplementation. Which form of iron is most commonly prescribed for oral administration?

Accepted Answer

Ferrous sulfate

Answer

Ferric citrate

Answer

Iron dextran

Answer

Ferrous fumarate

Question 10

What are the effects of niacin on HDL and triglycerides in the management of familial combined hyperlipidemia?

Accepted Answer

Increases HDL; lowers triglycerides

Answer

Decreases HDL; raises triglycerides

Answer

No significant effect on HDL; minor effect on triglycerides

Answer

Increases both HDL and triglycerides

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?